Search - tctmd.com

Displaying 401 - 417 of 417

Sort: Relevancy | Date

News Daily News

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

July 07, 2015

News Industry News

Hansen Medical® Announces Successful Enrollment of Initial Cohort in Artisan® U.S. Clinical Trial

July 06, 2015

News Industry News

SentreHEART Receives FDA Approval for the AMAZE Trial to Evaluate LARIAT Ligation of the Left Atrial

June 29, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Industry News

Medtronic Announces Acquisition of CardioInsight Technologies, Developer of Non-Invasive Cardiac Mapping System

June 19, 2015

News Daily News

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Todd Neale

January 28, 2015

News Daily News

Apixaban es Rentable comparado con Warfarina o Aspirina

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Caitlin E. Cox

February 26, 2014

Presentation

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Presenter: Paul Dorian

February 20, 2014

News Conference News TCT 2013

Innovation in Intervention: Perspectives from Industry

October 30, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

News Conference News ESC 2012

Study Looks at Global Mortality, Stroke Rates in A-fib Patients After ER Visit

Yael L. Maxwell

August 29, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

Presentation

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Presenter: S. Lee

July 11, 2012

News Daily News

Live Case Procedures Just as Safe as in Daily Practice

Caitlin E. Cox

February 21, 2012

News Daily News

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

L.A. McKeown

June 03, 2011

News Conference News

PARTNER: TAVI Cost Effective Compared With Standard Care

Jason Kahn

April 03, 2011

Advertisement

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

Hansen Medical® Announces Successful Enrollment of Initial Cohort in Artisan® U.S. Clinical Trial

SentreHEART Receives FDA Approval for the AMAZE Trial to Evaluate LARIAT Ligation of the Left Atrial

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

Medtronic Announces Acquisition of CardioInsight Technologies, Developer of Non-Invasive Cardiac Mapping System

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Apixaban es Rentable comparado con Warfarina o Aspirina

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Innovation in Intervention: Perspectives from Industry

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Study Looks at Global Mortality, Stroke Rates in A-fib Patients After ER Visit

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Live Case Procedures Just as Safe as in Daily Practice

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

PARTNER: TAVI Cost Effective Compared With Standard Care

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content